Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Oct;71(10):3381-3385.
doi: 10.4103/IJO.IJO_169_23.

Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy

K Sandeep  1 , Kavitha C Venugopal, Akshatha P Javagal, Pavana Acharya, S R Sreelekshmi, N Narendra, P K Nayana
Affiliations
Randomized Controlled Trial

Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy

K Sandeep et al. Indian J Ophthalmol. 2023 Oct.

Abstract

Purpose: To compare the efficacy of oral propranolol, oral rifampicin, and intravitreal anti-VEGF therapies on resolution-time and visual outcome in patients with central serous chorioretinopathy (CSCR).

Methods: A total of 30 patients with CSCR were randomized into three groups of 10 patients. Group A was given oral propranolol, Group B was given oral rifampicin 4 weeks each, and Group C was given 0.05 ml intravitreal injection of anti-VEGF. Comparisons of mean BCVA, contrast sensitivity, and central macular thickness (CMT) performed between baseline and follow-up at 4 weeks, 6 weeks, and 3 months.

Results: Statistically significant improvement in BCVA and contrast sensitivity was noted among all three groups. Complete resolution of SRF as indicated by CMT was seen at the end of 4 weeks in Group C, whereas there was a steady decline in CMT until 3 months in Groups A and B.

Conclusion: Intravitreal anti-VEGF therapy shows a significantly faster SRF resolution. However, oral propranolol and oral rifampicin could prove as a useful, cost-effective treatment of CSCR.

Keywords: Anti-VEGF; central serous chorioretinopathy; propranolol; rifampicin.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Age distribution
Figure 2
Figure 2
OCT image showing resolution of SRF at the end of 3 months
Figure 3
Figure 3
Change in contrast sensitivity with time
Figure 4
Figure 4
Change in CMT with time
See this image and copyright information in PMC

References

    1. Badar A, Khan S, Shah SU, Tahir M, Babree S. Comparison of oral rifampicin with observation alone in treatment of acute central serous Chorioretinopathy. International Journal of Retina. 2020;3 doi: 10.35479/ijretina.2020.vol003.iss001.103.
    1. Mohabati D, van Dijk EH, van Rijssen TJ, de Jong EK, Breukink MB, Martinez-Ciriano JP, et al. Clinical spectrum of severe chronic central serous chorioretinopathy and outcome of photodynamic therapy. Clinical Ophthalmology (Auckland, NZ) 2018;12:2167. - PMC - PubMed
    1. Chen LC, Ma JW, Shieh PC, Horng CT. Oral Treatment of Central Serous Chorioretinopathy Patients Using Propranolol Tablets. Pharmaceuticals. 2020;13:336. - PMC - PubMed
    1. Lim JW, Kim MU. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology. 2011;249:969–74. - PubMed
    1. Guengerich F. P. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 1999;39:1–17. - PubMed

Publication types

MeSH terms